Quick Answer
Aptevo Therapeutics Inc. reported Operating Income Loss of -$26.31 million for the year ending 2025.
- Aptevo Therapeutics Inc. showed a decrease of -7.0% in Operating Income Loss from 2024 to 2025.
- This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: -$11.10 million | Q2 2015: -$18.31 million | Q3 2015: -$13.19 million | Q4 2015: -$18.50 million | Q1 2016: -$12.98 million | Q2 2016: -$12.85 million | Q3 2016: -$90.53 million | Q4 2016: -$14.55 million | Q1 2017: -$12.13 million | Q2 2017: -$14.65 million | Q3 2017: -$10.35 million | Q1 2018: -$13.50 million | Q2 2018: -$12.44 million | Q3 2018: -$12.13 million | Q1 2019: -$11.44 million | Q2 2019: -$12.90 million | Q3 2019: -$11.46 million | Q1 2020: -$7.62 million | Q2 2020: -$6.81 million | Q3 2020: -$6.25 million | Q1 2021: -$6.89 million | Q2 2021: -$5.72 million | Q3 2021: -$4.75 million | Q1 2022: -$5.61 million | Q2 2022: -$7.56 million | Q3 2022: -$7.78 million | Q1 2023: -$7.76 million | Q2 2023: -$8.18 million | Q3 2023: -$6.56 million | Q1 2024: -$6.98 million | Q2 2024: -$6.02 million | Q3 2024: -$5.21 million | Q1 2025: -$6.48 million | Q2 2025: -$6.23 million | Q3 2025: -$7.61 million.
- Over the full 11 years of available data (2015 to 2025), Aptevo Therapeutics Inc.'s Operating Income Loss has grown by 56.9%.
- Historical annual values: Fiscal year 2025: -$26.31 million | Fiscal year 2024: -$24.60 million | Fiscal year 2023: -$28.88 million | Fiscal year 2022: -$28.64 million | Fiscal year 2021: -$21.40 million | Fiscal year 2020: -$27.49 million | Fiscal year 2019: -$40.96 million | Fiscal year 2018: -$51.67 million | Fiscal year 2017: -$53.95 million | Fiscal year 2016: -$138.77 million | Fiscal year 2015: -$61.10 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: